Baird raised the firm’s price target on Revvity (RVTY) to $138 from $136 and keeps an Outperform rating on the shares. The firm said they posted 3Q revenue/EPS ahead of consensus, with mixed revenue performance. The company continued to message stability in pharma/biotech, though customer spending on instruments remains constrained, particularly in China.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity Reports Strong Q3 Growth and New Share Buyback
- Morning Movers: Air Transport Services jumps following $3.1B take-private deal
- Revvity raises FY24 adjusted EPS view to $4.83-$4.87 from $4.70-$4.80
- Revvity reports Q3 adjusted EPS $1.28, consensus $1.12
- Revvity announces $1B share repurchase program